Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPT Regimen Plus Radiotherapy for Stage I/II NK/T-Cell Lymphoma
NCT07000617Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Peking University Cancer Hospital & Institute. Started Mar 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT07000617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000617.